The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

@article{Arber2016The2R,
  title={The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.},
  author={D. Arber and A. Orazi and R. Hasserjian and J. Thiele and M. Borowitz and M. L. Le Beau and C. Bloomfield and M. Cazzola and J. Vardiman},
  journal={Blood},
  year={2016},
  volume={127 20},
  pages={
          2391-405
        }
}
  • D. Arber, A. Orazi, +6 authors J. Vardiman
  • Published 2016
  • Medicine
  • Blood
  • The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. [...] Key Method The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical…Expand Abstract
    3,517 Citations

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    This study assesses the potential of using a TGFβ receptor inhibitor for the treatment of anemic patients with myeloproliferetive neoplasms. TGFβ signaling is known to be abnormally… Expand
    ConditionsMyeloproliferative Neoplasm
    InterventionDrug
    OBSERVATIONAL CLINICAL TRIAL
    Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by clonal expansion of myeloid progenitors (blasts) in the bone marrow and peripheral blood.Several studies have… Expand
    ConditionsAcute Myeloid Leukemia
    InterventionDiagnostic Test, Genetic
    INTERVENTIONAL CLINICAL TRIAL
    Myelodysplastic syndromes (MDS) are the most frequent myeloid neoplasms in Western Countries.They mainly affect patients aged 65 years or older. This is a very heterogenous group… Expand
    ConditionsHigh-risk Myelodysplastic Syndromes With Excess Blasts
    InterventionDiagnostic Test
    OBSERVATIONAL CLINICAL TRIAL
    The RUXOREL-MF observational study includes patients with primary and post-essential thrombocythemia/post-polycythemia vera myelofibrosis (MF) being treated with the oral JAK1… Expand
    ConditionsMyelofibrosis
    InterventionDrug
    The 2016 revision to the World Health Organization classification of myelodysplastic syndromes
    • Ming Hong, G. He
    • Medicine
    • Journal of translational internal medicine
    • 2017
    • 20
    • PDF
    Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia.
    • J. Leonard, P. Martin, G. Roboz
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2017
    • 31
    An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL)
    • 11

    References

    SHOWING 1-10 OF 166 REFERENCES
    Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
    • 172
    Should myeloid and lymphoid neoplasms with PCM1‐JAK2 and other rearrangements of JAK2 be recognized as specific entities?
    • 43
    Revised international prognostic scoring system for myelodysplastic syndromes.
    • 1,587
    • PDF
    Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system.
    • 208
    • PDF